Aliada Therapeutics

Boston, United States Founded: 2021 • Age: 5 yrs Acquired By AbbVie
Provider of drug research development services for multiple therapeutic areas
Annual revenue - Latest available
Total funding $33.0M 1 rounds
Employees - Tracked headcount
Investors 3 Known backers
Products - Services tracked
Competitors 9 Brand Intelligence

About Aliada Therapeutics

Aliada Therapeutics is a company based in Boston (United States) founded in 2021 was acquired by AbbVie in October 2024. Aliada Therapeutics has raised $33 million across 1 funding round from investors including AbbVie, RA Capital and Johnson & Johnson Innovation – JJDC. Aliada Therapeutics operates in a competitive market with competitors including WuXi AppTec, Eurofins Scientific, Ipsen, ANI Pharmaceuticals and Red Nucleus, among others.

  • Headquarter Boston, United States
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $33 M (USD)

    in 1 rounds

  • Latest Funding Round
    $33 M (USD), Seed

    Jul 06, 2021

  • Investors
    AbbVie

    & 2 more

  • Employee Count
    Not available
  • Acquired by
    AbbVie

    (Oct 28, 2024)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

People of Aliada Therapeutics

Headcount 10-50
Employee Profiles 8
Employee Profiles
People
Danijela Dukovski
Senior Director, Biology
People
J. Michael Ryan
Chief Medical Officer
People
Keith Canada
Vice President, Head Of Platform Technology
People
Steven Sweeney
President And Chief Operating Officer

Unlock access to complete

Funding Insights of Aliada Therapeutics

Aliada Therapeutics has successfully raised a total of $33M through 1 strategic funding round. The most recent funding activity was a Seed round of $33 million completed in July 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in Aliada Therapeutics

Aliada Therapeutics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include AbbVie, RA Capital and Johnson & Johnson Innovation – JJDC.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm backed by Johnson & Johnson
Locked Locked Locked
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
Locked Locked Locked
Biopharmaceutical research and drug development are conducted globally by AbbVie.
Locked Locked Locked
Premium access

Investor details for Aliada Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Aliada Therapeutics

Investments
Premium access

Investment portfolio details for Aliada Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - Aliada Therapeutics

Premium access

Detailed financials for Aliada Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Aliada Therapeutics Comparisons

Aliada Therapeutics Primary company
Description
Provider of drug research & development services for multipl...
Location
Boston, United States
Founded Year
2021
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for Aliada Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Aliada Therapeutics

Aliada Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as WuXi AppTec, Eurofins Scientific, Ipsen, ANI Pharmaceuticals and Red Nucleus, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Provider of CRO and CDMO services
Locked Locked Locked
Laboratory testing and contract research services are provided globally.
Locked Locked Locked
Biopharmaceutical company focused on developing and commercializing innovative treatments in oncology, rare disease, and neuroscience to improve patient health outcomes
Locked Locked Locked
Branded and generic prescription drugs are developed, manufactured, and marketed.
Locked Locked Locked
Advisory, scientific, and medical communications provided for pharmaceutical industry.
Locked Locked Locked
Regulatory support, brand differentiation, and prototyping services are provided.
Premium access

Detailed competitors of Aliada Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Aliada Therapeutics

Premium access

Complete news archive for Aliada Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Aliada Therapeutics

Aliada Therapeutics was founded in 2021.

Aliada Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.

Aliada Therapeutics is a funded company, having raised a total of $33M across 1 funding round to date.

Aliada Therapeutics, backed by 33000000.0 from Johnson Johnson Innovation JJDC, RA Capital Management, focuses on providing healthcare solutions, biopharma outsourcing, and diversified. Provider of drug research development services for multiple therapeutic areas. Driving innovation, growth, and excellence in its industry sectors.

Aliada Therapeutics's top competitors include WuXi AppTec, ANI Pharmaceuticals and Aptar.

Aliada Therapeutics has 3 investors. Key investors include AbbVie, RA Capital, and Johnson & Johnson Innovation – JJDC.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available